Search Result

Results for "

hypoglycemic activities.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (2) Akt (1) AMPK (3) Androgen Receptor (1) Apoptosis (6) Autophagy (2) Caspase (1) Cholinesterase (ChE) (1) COX (3) Cuproptosis (1) Dipeptidyl Peptidase (2) Drug Derivative (3) Endogenous Metabolite (9) ERK (2) FBPase (1) GLP Receptor (1) GLUT (4) Glycosidase (8) HIF/HIF Prolyl-Hydroxylase (2) IKK (1) Influenza Virus (5) Insulin Receptor (2) Integrin (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (3) Keap1-Nrf2 (4) LDLR (1) Mitochondrial Metabolism (5) MMP (2) Monoamine Oxidase (1) NF-κB (5) p38 MAPK (1) PAK (1) PCSK9 (1) PDGFR (1) Phosphatase (4) PPAR (4) Reactive Oxygen Species (ROS) (2) Reference Standards (9) ROS Kinase (2) SGLT (1) SOD (2) TRP Channel (1) Tyrosinase (1) UGT (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (5) Endocrinology (3) Infection (6) Inflammation/Immunology (22) Metabolic Disease (43) Neurological Disease (9)

By Targets:

Adrenergic Receptor (2)

Akt (1)

AMPK (3)

Androgen Receptor (1)

Apoptosis (6)

Autophagy (2)

Caspase (1)

Cholinesterase (ChE) (1)

COX (3)

Cuproptosis (1)

Dipeptidyl Peptidase (2)

Drug Derivative (3)

Endogenous Metabolite (9)

ERK (2)

FBPase (1)

GLP Receptor (1)

GLUT (4)

Glycosidase (8)

HIF/HIF Prolyl-Hydroxylase (2)

IKK (1)

Influenza Virus (5)

Insulin Receptor (2)

Integrin (2)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JAK (3)

Keap1-Nrf2 (4)

LDLR (1)

Mitochondrial Metabolism (5)

MMP (2)

Monoamine Oxidase (1)

NF-κB (5)

p38 MAPK (1)

PAK (1)

PCSK9 (1)

PDGFR (1)

Phosphatase (4)

PPAR (4)

Reactive Oxygen Species (ROS) (2)

Reference Standards (9)

ROS Kinase (2)

SGLT (1)

SOD (2)

TRP Channel (1)

Tyrosinase (1)

UGT (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (5)

Endocrinology (3)

Infection (6)

Inflammation/Immunology (22)

Metabolic Disease (43)

Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6653

Lentinan 5+ Cited Publications	JAK Keap1-Nrf2 Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering ^[1][4].

HY-N0205

Pulchinenoside C 5 Publications Verification Anemoside B4	Others	Cancer
Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.

HY-N0416

Cucurbitacin B Maximum Cited Publications 11 Publications Verification	HIF/HIF Prolyl-Hydroxylase Integrin Autophagy Apoptosis Endogenous Metabolite ROS Kinase COX	Others Neurological Disease Inflammation/Immunology Cancer
Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity .

HY-N0661

Alliin 3 Publications Verification	Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alliin, an orally active sulfoxide compound that can be isolated from garlic, exhibits hypoglycemic, antioxidant, anti-inflammatory and antitumor activities .

HY-N0655

D-Pinitol 1 Publications Verification 3-O-Methyl-D-chiro-inositol	Influenza Virus	Infection Cardiovascular Disease Inflammation/Immunology
D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .

HY-N0807

Swertiamarin 1 Publications Verification	MMP NF-κB JAK Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-N0761

Isoferulic acid 3 Publications Verification 3-Hydroxy-4-methoxycinnamic acid	Adrenergic Receptor Influenza Virus	Infection Metabolic Disease Inflammation/Immunology Endocrinology
Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes .

HY-N8264

Moringin 1 Publications Verification	TRP Channel	Neurological Disease Inflammation/Immunology Cancer
Moringin is a potent and selective TRPA1 ion channel natural agonist with an EC₅₀ of 3.14 μM. Moringin does not activate or activates very weakly the vanilloids somatosensory channels TRPV1, TRPV2, TRPV3 and TRPV4, and the melastatin cooling receptor TRPM8. Moringin has hypoglycemic, antimicrobial, anti-inflammatory, anticancer and neuroprotection activities .

HY-N2413

Gomisin D	PDGFR UGT Reactive Oxygen Species (ROS) Apoptosis Tyrosinase p38 MAPK Akt ERK COX Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology
Gomisin D is an orally active lignan that binds to PDGFRβ with a K_d of 10 μM. By targeting PDGFRβ to regulate signaling pathways, Gomisin D inhibits the activation and proliferation of hepatic stellate cells and promotes their apoptosis, thereby ameliorating hepatic fibrosis. Gomisin D exhibits multiple activities such as photoprotection, antimelanogenesis, antioxidant effects, and hypoglycemic activity. Gomisin D can be used in studies related to diabetes, Alzheimer's disease, and hepatic fibrosis .

HY-W011651

Carbutamide BZ-55	Phosphatase	Metabolic Disease
Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity .

HY-N0299

Stachyose hydrate 1 Publications Verification	Endogenous Metabolite Apoptosis	Metabolic Disease Inflammation/Immunology
Stachyose hydrate is an orally active prebiotic that enhances the growth and activity of beneficial bacteria. Stachyose hydrate has hypoglycemic effects and can improve inflammation by regulating gut microbiota. In addition, Stachyose hydrate can induce plant cell apoptosis (Apoptosis). Stachyose hydrate can be used in research on inflammation, gastrointestinal diseases, and agriculture .

HY-136093A

Lixumistat acetate 1 Publications Verification IM156; HL156A; HL271 acetate	Mitochondrial Metabolism AMPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Lixumistat (IM156) acetate is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat acetate strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat acetate exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .

HY-Y0624

4-Pentenoic acid	Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization .

HY-128447

Allyl methyl sulfide 1 Publications Verification	Endogenous Metabolite SOD NF-κB GLUT	Metabolic Disease Inflammation/Immunology
Allyl methyl sulfide is an orally active organic sulfide. Allyl methyl sulfide is one of the main active ingredients in garlic volatile metabolites. Allyl methyl sulfide can be extracted from garlic. Allyl methyl sulfide enhances SOD activity, inhibits NF-κB signaling pathway, and upregulates pancreatic GLUT2 expression. Allyl methyl sulfide has significant antioxidant, anti-inflammatory and hypoglycemic activities. Allyl methyl sulfide can be used in the research of diabetes and its complications .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC₅₀ of 0.57 nM for GLP-1R and an EC₅₀ of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .

HY-136093B

Lixumistat 1 Publications Verification IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism AMPK	Neurological Disease Inflammation/Immunology
Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .

HY-142026

Vitisin A (+)-Vitisin A	Caspase ERK NF-κB Influenza Virus PAK LDLR PPAR PCSK9 Androgen Receptor Keap1-Nrf2 Monoamine Oxidase Cholinesterase (ChE) IKK Wnt β-catenin Reactive Oxygen Species (ROS) Apoptosis Cuproptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC₅₀ values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases .

HY-136093

Lixumistat hydrochloride 1 Publications Verification HL271; IM156 hydrochloride; HL156A hydrochloride	Mitochondrial Metabolism AMPK	Neurological Disease
Lixumistat (IM156) hydrochloride is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat hydrochloride strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat hydrochloride exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .

HY-113631

Amorfrutin B	PPAR	Neurological Disease Metabolic Disease
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-Y0004

2-Pyridinemethanol	Drug Derivative	Metabolic Disease
2-Pyridinemethanol is a pyridylalcohol, with hypoglycemic activity .

HY-N4147

Eleutheroside D	Others	Metabolic Disease Inflammation/Immunology
Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities . Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272) .

HY-N0416R

Cucurbitacin B (Standard)	HIF/HIF Prolyl-Hydroxylase Reference Standards Integrin Autophagy Apoptosis Endogenous Metabolite ROS Kinase COX	Others Neurological Disease Inflammation/Immunology Cancer
Cucurbitacin B (Standard) is the analytical standard of Cucurbitacin B. This product is intended for research and analytical applications. Cucurbitacin B belongs to a class of highly oxidized tetracyclic triterpenoids and is oral active. Cucurbitacin B inhibits tumor cell growth, migration and invasion and cycle arrest, but induces cell apoptosis. Cucurbitacin B has potent anti-inflammatory, antioxidant, antiviral, hypoglycemic, hepatoprotective, neuroprotective activity .

HY-128447R

Allyl methyl sulfide (Standard)	Reference Standards Endogenous Metabolite SOD NF-κB GLUT	Metabolic Disease Inflammation/Immunology
Allyl methyl sulfide (Standard) is the analytical standard of Allyl methyl sulfide (HY-128447). This product is intended for research and analytical applications. Allyl methyl sulfide is an orally active organic sulfide. Allyl methyl sulfide is one of the main active ingredients in garlic volatile metabolites. Allyl methyl sulfide can be extracted from garlic. Allyl methyl sulfide enhances SOD activity, inhibits NF-κB signaling pathway, and upregulates pancreatic GLUT2 expression. Allyl methyl sulfide has significant antioxidant, anti-inflammatory and hypoglycemic activities. Allyl methyl sulfide can be used in the research of diabetes and its complications .

HY-N12241

Sterebin F	Others	Others
Sterebin F is a steroid isolated from the Stevia rebaudiana leaves. Sterebin F has hypoglycemic activity .

HY-135670B

Glycosidase-IN-2	Glycosidase	Metabolic Disease
Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity .

HY-W011651R

Carbutamide (Standard) BZ-55 (Standard)	Phosphatase Reference Standards	Metabolic Disease
Carbutamide (Standard) is the analytical standard of Carbutamide. This product is intended for research and analytical applications. Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity .

HY-135670A

β-glycosidase-IN-1	Glycosidase	Metabolic Disease
β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity .

HY-W011651S

Carbutamide-d9 BZ-55-d9	Isotope-Labeled Compounds	Metabolic Disease
Carbutamide-d₉ (BZ-55-d₉) is the deuterium labeled Carbutamide. Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity .

HY-121565

SaRI 59-801	Insulin Receptor	Metabolic Disease Endocrinology
SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .

HY-N0661R

Alliin (Standard)	Reference Standards Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alliin (Standard) is the analytical standard of Alliin. This product is intended for research and analytical applications. Alliin, an orally active sulfoxide compound that can be isolated from garlic, exhibits hypoglycemic, antioxidant, anti-inflammatory and antitumor activities .

HY-135670

Glycosidase-IN-1	Glycosidase	Metabolic Disease
Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity .

HY-N0807R

Swertiamarin (Standard)	Reference Standards MMP NF-κB JAK Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .

HY-168706

LXQ-87	Phosphatase	Metabolic Disease
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC₅₀ of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .

HY-173183

α-Glucosidase-IN-87	Glycosidase	Metabolic Disease
α-Glucosidase-IN-87 (Compound 11c) is an orally active α-glucosidase inhibitor with an IC₅₀ value of 119.7 μM. α-Glucosidase-IN-87 has hypoglycemic activity and can be used in the research of metabolic diseases such as diabetes .

HY-162893

SX29	Glycosidase	Metabolic Disease
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC₅₀ value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .

HY-N0655R

D-Pinitol (Standard) 3-O-Methyl-D-chiro-inositol (Standard)	Reference Standards Influenza Virus	Infection Cardiovascular Disease Inflammation/Immunology
D-Pinitol (Standard) is the analytical standard of D-Pinitol. This product is intended for research and analytical applications. D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system . D-pinitol has antiviral and larvicidal activities .

HY-150723

PBI-6DNJ	Glycosidase	Metabolic Disease
PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a K_i of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research .

HY-163005

α-Glucosidase-IN-43	Glycosidase	Metabolic Disease
α-Glucosidase-IN-43 (compound AS14) is an α-glucosidase inhibitor (IC₅₀: 4.32 μM) with acute hypoglycemic activity. α-Glucosidase-IN-43 exhibits safety and in vivo efficacy, is nontoxic to normal mouse fibroblasts, and is able to rescue streptozotocin (HY-13753)-induced diabetic rats. α-Glucosidase-IN-43 can be used to study postprandial hyperglycemia in diabetic patients .

HY-173503

DS-1150b	GLUT	Metabolic Disease
DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .

HY-N0761R

Isoferulic acid (Standard) 3-Hydroxy-4-methoxycinnamic acid (Standard)	Reference Standards Adrenergic Receptor Influenza Virus	Infection Metabolic Disease Inflammation/Immunology Endocrinology
Isoferulic acid (Standard) (3-Hydroxy-4-methoxycinnamic acid (Standard)) is the analytical standard of Isoferulic acid (HY-N0761). This product is intended for research and analytical applications. Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes .

HY-Y0624R

4-Pentenoic acid (Standard)	Reference Standards Endogenous Metabolite Mitochondrial Metabolism	Metabolic Disease
4-Pentenoic acid (Standard) is the analytical standard of 4-Pentenoic acid (HY-Y0624). This product is intended for research and analytical applications. 4-Pentenoic acid is a medium-chain unsaturated fatty acid. 4-Pentenoic acid has hypoglycemic and fatty acid oxidation inhibitory activities. 4-Pentenoic acid can affect blood glucose metabolism and energy metabolism through mechanisms such as inhibiting long-chain fatty acid oxidation, reducing gluconeogenesis, and promoting glucose utilization.

HY-I0786

(2S,4R)-Teneligliptin	Dipeptidyl Peptidase	Metabolic Disease
(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). (2S,4R)-Teneligliptin increases the plasma concentration of active glucagon-like peptide-1 (GLP-1), which promotes insulin secretion in response to elevated blood glucose levels, exerting hypoglycemic activity. (2S,4R)-Teneligliptin is promising for research of type 2 diabetes .

HY-19904A

(+/-)-Adomeglivant (+/-)-LY2409021	Endogenous Metabolite	Metabolic Disease
(+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .

HY-173217

PPARα agonist 5	PPAR Phosphatase	Cardiovascular Disease Metabolic Disease
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC₅₀: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .

HY-126969

C333H	PPAR	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-180784

Hypoglycemic agent 4	Drug Derivative Dipeptidyl Peptidase SGLT GLUT	Metabolic Disease
Hypoglycemic agent 4 (Compound 5b) is a tetrahydroacridine derivative with orally active hypoglycemic activity. Hypoglycemic agent 4 has a good binding affinity for the key diabetic targets: DPP-IV, SGLT1, and GLUT2. Hypoglycemic agent 4 can inhibit glucose diffusion. Hypoglycemic agent 4 can reduce fasting blood sugar in Streptozotocin (HY-13753)-induced diabetic rats and its effect is comparable to Gliclazide (HY-B0753). Hypoglycemic agent 4 can be used for research of type 2 diabetes .

HY-Y0004R

2-Pyridinemethanol (Standard)	Drug Derivative Reference Standards	Metabolic Disease
2-Pyridinemethanol is a pyridylalcohol, with hypoglycemic activity .

HY-118523

AL-321	Endogenous Metabolite	Metabolic Disease
AL-321 is an insulin sensitizer. AL-321 exhibits significant hypoglycemic and hypolipidemic activities in insulin resistance models. AL-321 can be used in the research of hereditary obesity-related diabetes .

HY-N19811

Eleuthoside B	Glycosidase	Metabolic Disease
Eleuthoside B is a naphthyl gentiobioside identified from the bulbs of Eleutherine americana. Eleuthoside B has an IC₅₀ >1.00 mM against α-glucosidase, and it is not the main contributor to the antidiabetic (hypoglycemic) activity exhibited by the plant extract .

HY-N17985

Kalopanaxsaponin H	Others	Metabolic Disease Inflammation/Immunology
Kalopanaxsaponin H is an hederagenin glycoside (saponin) with no hypoglycemic activity upon intraperitoneal injection. Kalopanaxsaponin H can be metabolized by human intestinal bacteria into Kalopanaxsaponin I, Kalopanaxsaponin A, hederagenin 3-O-α-L-arabinopyranoside and hederagenin, among which Kalopanaxsaponin I and hederagenin are the main metabolites. Kalopanaxsaponin H is isolated from the stem bark of Kalopanax pictus and is used in diabetes-related research .

Cat. No.	Product Name	Target	Research Area